Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Healthy Clinical Trial

Official title:

Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06329063
• Other study ID #: BAM_lab_eyetracking_03
• Status: Recruiting
• Phase: N/A
• Start date: March 5, 2024
• Est. completion date: July 30, 2025

Study information

• Verified date: April 2024
• Source: University of Electronic Science and Technology of China
• Contact: Weihua Zhao, Dr
• Phone: 86-28-61830811
• Email: zarazhao.uestc[@]outlook.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Description:

Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: July 30, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.

• Normal or corrected-normal version

Exclusion Criteria:

• History of neuropsychiatric diseases.

• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.

• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.

• History of renal diseases, including renal stones or renal failure.

• History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus

• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.

• Infections such as COVID-19 or influenza, or unexplained fever.

• Subjects with hypertension (BP =130/80mmHg) or hypotension (BP = 90/60mmHg).

• History of alcohol or drug abuse; smoker (= 10 cigarettes or = 3 cigars or = 3 pipes/day); smoker using e-cigarettes.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Vasopressin
Administration of vasopressin (20 IU) (oral spray)
• Placebo
Administration of placebo (oral spray)

Locations

Country	Name	City	State
China	University of Electronic Science and Technology of China	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration	Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.	75 minutes - 105 minutes after treatment
Secondary	First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration	Comparison of first saccade latencies between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.	75 minutes - 105 minutes after treatment
Secondary	Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration	Comparison of mean fixation durations between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.	75 minutes - 105 minutes after treatment